has executed an exclusive agreement with Catalent Pharma Solutions to develop both assets using Catalent’s patented, commercially proven OptiDose technology. OptiDose is a state-of-the-art manufacturing process that allows for faster, more efficient manufacturing (up to 100,000 units/hr), optimized drug delivery for better efficacy and significant COGm savings (approx. 75% less costly than current manufacturing technologies).

IP, in the form of an existing body of patents (28 currently) – along with the filing of multiple provisional applications (beginning Q1-2015) – assure CTx and their investment partners, strong IP continuity and protection throughout development and into divestiture or commercialization.

Two stimulants (both having been in clinical use for 50+ years) account for >90% of ADHD Rx’s written. These stimulants generally provide “partial-day” therapeutic efficacy, of 6-12 hours. Ongoing research suggests at least half of these patients require additional dosing to obtain “full-day” therapeutic efficacy. This “combination dosing” (taking an extended-release dose in the morning combined with an immediate release dose in the afternoon) often produces negative consequences, including insomnia, weight-loss, poor patient compliance, irritability/agitation, and overall therapeutic failure.

CTx's development of these two assets – using the two aforementioned, generic stimulants –target the large, unmet need for single-dose, “full-day” therapeutic efficacy. CTx expects to have Immediate traction in both this $2-$3 Billion (projected) “combination-dose” market, as well as the “overall” $9B ADHD market.